Verona Pharma Plc ADR (NASDAQ: VRNA) on Tuesday, soared 9.02% from the previous trading day, before settling in for the closing price of $34.94. Within the past 52 weeks, VRNA’s price has moved between $11.39 and $40.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -39.77% over the past five years. The company achieved an average annual earnings per share of -200.00%. With a float of $68.82 million, this company’s outstanding shares have now reached $80.44 million.
Let’s look at the performance matrix of the company that is accounted for 79 employees. In terms of profitability, gross margin is 80.41%, operating margin of -2370.63%, and the pretax margin is -2352.52%.
Verona Pharma Plc ADR (VRNA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Verona Pharma Plc ADR is 15.90%, while institutional ownership is 67.16%. The most recent insider transaction that took place on Nov 18 ’24, was worth 88,800. In this transaction Director of this company bought 20,000 shares at a rate of $4.44, taking the stock ownership to the 940,003 shares. Before that another transaction happened on Nov 11 ’24, when Company’s President and CEO sold 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 15,202,352 shares in total.
Verona Pharma Plc ADR (VRNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -200.00% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Verona Pharma Plc ADR (VRNA) is currently performing well based on its current performance indicators. A quick ratio of 13.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 548.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.94, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Verona Pharma Plc ADR (NASDAQ: VRNA) saw its 5-day average volume 1.08 million, a positive change from its year-to-date volume of 0.93 million. As of the previous 9 days, the stock’s Stochastic %D was 29.63%. Additionally, its Average True Range was 1.87.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 92.15%, which indicates a significant increase from 76.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.95% in the past 14 days, which was higher than the 59.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.12, while its 200-day Moving Average is $21.78. Nevertheless, the first resistance level for the watch stands at $39.27 in the near term. At $40.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $42.60. If the price goes on to break the first support level at $35.94, it is likely to go to the next support level at $33.79. Assuming the price breaks the second support level, the third support level stands at $32.61.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
Market capitalization of the company is 3.12 billion based on 80,440K outstanding shares. Right now, sales total 0 K and income totals -54,370 K. The company made 5,620 K in profit during its latest quarter, and -42,960 K in sales during its previous quarter.
